Author Archives: Ana de Barros PhD

Biscayne Licenses Rights of Antiepileptic Therapy Candidate to Chinese Biopharma

Biscayne Neurotherapeutics has licensed the Chinese rights to its investigative antiepileptic therapy BIS-001ER to Global Drug Development Centre (GDCC) China in Taiwan, China, Hong Kong, and Macau. Biscayne is developing BIS-001ER to treat refractory forms of focal epilepsy, including catastrophic pediatric-onset epilepsies such as Dravet syndrome and Lennox Gastaut. “BIS-001ER is…